Lyme Disease & HYPERBARICS

The United States Center for Disease Control is now reporting that there are over 300,000 new cases of Lyme disease each year. Additionally, as the disease remains difficult to identify and diagnose, the definitive number of people affected is currently unknown, making this the fastest growing infectious disease in the US. The tick-borne bacterium or spirochete (Borrelia burgdorferi) is protected by the biofilm it creates to hide from the immune system, and can often lie dormant for years. Often antibiotic interventions alone fall short in providing much needed symptomatic relief. Hyperbaric oxygen therapy (HBOT) has been shown to elevate tissue oxygenation, which can be lethal to this bacteria, increase white blood cell activity and enhance antimicrobial responses. Oxygen is essential in the killing of bacteria and by exponentially raising oxygen levels throughout the body, the efficiency of bactericidal action of white blood cells can be enhanced dramatically. Clinical data and case reports have demonstrated the lasting benefits of HBOT for Lyme disease with the following:

Enhance Antibacterial Effects with HBOT

  • Reduces Tumor Hypoxia
  • Decreases Tumor Drug Resistance Allows for Optimal Therapy Dosage to be Attained
  • Better Radiation Therapy Results
  • Increases Post-Op Fibroblast Activation
  • Improves Chemotherapy Outcome
  • Enhances Glioblastoma Treatment

Reduce Tumor Aggressiveness with HBOT

  • Weakens Hypoxic Tumors
  • Targets Metastatic Tumors

Increase Natural Killer Cell Activity and Function with HBOT

  • Increases Oxy-Radical Production
  • Amplifies Apoptosis Effect
  • Regresses Tumor Volume

Reduce Side Effects of "Conventional" Cancer Therapies & Treatments with HBOT

  • Reduces Radiation Therapy Side Effects
  • Decreases Chemotherapy Side Effects
  • Accelerates Post-Operative Healing & Prevents Infection
  • Reduces Chemo-Brain Syndrome Symptoms

Enhance IV Cancer Treatments with HBOT

  • Increases Intravenous Vitamin C Therapy Effect

Cancer Prevention with HBOT

  • Decreases Inflammatory Markers
  • Normalizes Intracellular Oxygen Levels
  • Reduces Risk of Pathogenic Inflammatory‑ Related Tumors
  • Stimulates Cellular Detoxification
  • Supports Cellular Energy Processes for Optimal DNA Repair

Study: Tumor Regression Stimulated by HBOT

A non-randomized trial was conducted with 29 patients to evaluate the efficacy of radiotherapy combined with HBOT, in patients with a malignant glioma. Fifteen patients were irradiated daily after HBOT and fourteen other irradiated patients were treated without HBOT. In the HBOT group, 11 of 15 patients (73 percent) showed 50 percent tumor regression. In the non-HBOT group, only four of 14 patients (29 percent) underwent tumor regression. The median survival rate in patients with HBOT doubled that of the non-HBOT group (24 months vs. 12 months) respectively. No serious side-effects were observed in the HBOT patients. This provides additional support for HBOT to be a beneficial treatment for malignant gliomas